Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial

por Lan, Chun-Yan, Zhao, Jing, Yang, Fan, Xiong, Ying, Li, Rong, Huang, Yu, Wang, Jing, Liu, Chang, Bi, Xue-Han, Jin, Hai-Hong, Meng, Jin, Zhao, Wei-Hong, Zhang, Li, Wang, Ya-Fei, Zheng, Min, Huang, Xin
Publicado 2022